ArticleCancer immunology, immunotherapy : CII2018

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies.

Paulina Nowakowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.